Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared

Biotech Giants' SG&A Spending: A Decade of Divergence

__timestampDynavax Technologies CorporationMadrigal Pharmaceuticals, Inc.
Wednesday, January 1, 20141776300015746000
Thursday, January 1, 20152218000013392000
Friday, January 1, 2016372570009290000
Sunday, January 1, 2017273670007672000
Monday, January 1, 20186477000015293000
Tuesday, January 1, 20197498600022648000
Wednesday, January 1, 20207925600021864000
Friday, January 1, 202110015600037318000
Saturday, January 1, 202213140800048130000
Sunday, January 1, 2023152946000108146000
Loading chart...

Unleashing the power of data

SG&A Spending Patterns: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Dynavax Technologies Corporation and Madrigal Pharmaceuticals, Inc. have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Dynavax's SG&A expenses surged by over 760%, peaking in 2023. This reflects their aggressive expansion and strategic investments. In contrast, Madrigal Pharmaceuticals, while also increasing their SG&A spending, exhibited a more moderate growth of approximately 590% over the same period. Notably, Madrigal's expenses saw a significant jump in 2023, reaching nearly 71% of Dynavax's peak spending. This divergence highlights differing strategic priorities: Dynavax's focus on rapid scaling versus Madrigal's steady growth approach. As these companies continue to evolve, their SG&A patterns offer valuable insights into their operational strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025